# Synthesis of spiroacetal-triazoles as privileged natural product-like scaffolds using "click chemistry"

Ka Wai Choi and Margaret A. Brimble\*

Department of Chemistry, University of Auckland, 23 Symonds St, Auckland, New Zealand TEL: +64 9 3737599 ext. 88259; FAX: +64 9 3737422; Email: m.brimble@auckland.ac.nz

### **Supplementary Information**

# General

Experiments requiring anhydrous conditions were performed under a dry nitrogen or argon atmosphere using oven- or flame-dried apparatus and standard techniques in handling air- and/or moisture-sensitive materials unless otherwise stated. Anhydrous dichloromethane (CH<sub>2</sub>Cl<sub>2</sub>) and triethylamine (NEt<sub>3</sub>) were distilled from calcium hydride; anhydrous tetrahydrofuran (THF) was distilled from sodium wire; anhydrous dry toluene was distilled from sodium wire. Solvents used (except for Et<sub>2</sub>O) for reactions, work-up extractions and chromatographic purifications were distilled, unless otherwise stated. Commercial reagents were analytical grade or were purified by standard procedures prior to use.<sup>1</sup> Separation of mixtures was performed by flash chromatography using Kieselgel S 63-100 µm (Riedel-de-Hahn) silica gel with the indicated eluent. Mass spectra were recorded on a VG-70SE mass spectrometer at a nominal accelerating voltage of 70 eV for low resolution and at a nominal resolution of 5000 to 10000 as appropriate for high resolution. Ionisation was effected using electron impact ( $EI^+$ ), fast atom bombardment (FAB<sup>+</sup>) using 3-nitrobenzyl alcohol as the matrix or chemical ionisation (CI<sup>+</sup>) using ammonia as a carrier gas. Major and significant fragments are quoted in the form x (y), where x is the mass to charge ratio (m/z) and y is the percentage abundance relative to the base peak (100%). Infrared spectra were obtained using a Perkin Elmer Spectrum 1000 Fourier Transform Infrared spectrometer as a thin film between sodium chloride plates. Absorption peaks are reported as wavenumbers ( $\nu$ , cm<sup>-1</sup>). NMR spectra were recorded on either a Bruker DRX300 spectrophotometer operating at 300 MHz for <sup>1</sup>H nuclei and 75 MHz for <sup>13</sup>C nuclei. or on a Bruker DRX400 spectrophotometer operating at 400 MHz for <sup>1</sup>H nuclei and 100 MHz for <sup>13</sup>C nuclei, at ambient temperature. <sup>1</sup>H NMR chemical shifts are reported in parts per million (ppm) relative to the tetramethylsilane peak ( $\delta 0.00$  ppm). <sup>1</sup>H NMR values are reported as chemical shift  $\delta$ , relative integral, multiplicity (s, singlet; d, doublet; t, triplet; q, quartet; quintet; m, multiplet), coupling constant (J, Hz) and assignment. Coupling constants were taken directly from the spectra.  $^{13}$ C NMR chemical shifts are reported in ppm relative to the chloroform peak ( $\delta$ 77.0 ppm). <sup>13</sup>C NMR values are reported as chemical shifts  $\delta$ , multiplicity and assignment. Assignments were made with the aid of DEPT, COSY, HSQC, HMBC and NOESY experiments.

# Synthesis of triazole 14a-g

General procedures for 1,3-dipolar cycloaddition of azide 5a to alkynes 6

#### Method A: For terminal alkynes with catalysis by Cul•[P(OEt)<sub>3</sub>]

To a solution of azide **5a** and alkyne **6** (50.0–100  $\mu$ L) in anhydrous toluene (250–500  $\mu$ L) under an atmosphere of argon was added CuI•[P(OEt)<sub>3</sub>] (0.10–0.12 equiv.). The resulting mixture was heated to reflux for 1 h. After cooling to room temperature, the mixture was purified directly by flash chromatography using hexane–EtOAc as eluent to give the spiroacetal containing a 1,4-disubstituted triazole substituent.

#### Method B: For symmetrical internal alkynes

A solution of azide **5a** and alkyne **6** (100  $\mu$ L) in anhydrous toluene (500  $\mu$ L) was heated to reflux for 1 h. The reaction mixture was purified directly by flash chromatography using hexane–EtOAc as eluent to give the spiroacetal containing a 1,4,5-trisubstituted triazole substituent.

#### Method C: For trimethylsilylacetylene

A solution of azide **5a** and trimethylsilylacetylene **6** (50.0–100  $\mu$ L) in anhydrous toluene (500  $\mu$ L) was heated at 110 °C in a sealed vessel. If the cycloaddition was not complete in 18 h (TLC), a second portion of trimethylsilylacetylene (50.0–100  $\mu$ L) was added and the mixture was heated at 110 °C overnight. The reaction mixture was purified directly by flash chromatography using hexane–EtOAc as eluent to give the spiroacetal containing a 1,4,5-trisubstituted triazole substituent.

## 4-[2''-(Benzyloxy)ethyl]-1-{(2'S\*,6'S\*,8'S\*)-8'-(*tert*-butyldiphenylsilyloxymethyl)-1',7'dioxaspiro[5.5]undecan-2'-yl}-1*H*-1,2,3-triazole (14a)

Method A: The *title compound* **14a** (39.3 mg, 98%) was prepared as a pale yellow oil from azide **5a** (30.0 mg, 64.4  $\mu$ mmol), 1-(benzyloxy)but-3-yne (**6a**, 100  $\mu$ L) and CuI•[P(OEt)<sub>3</sub>] (2.53 mg, 7.10  $\mu$ mol) in toluene (500  $\mu$ L) using the general procedure (method A) described above. Purification was carried out by flash chromatography using hexane–EtOAc (19:1, 7:3 to 1:1) as eluent. HRMS (FAB): found MH<sup>+</sup>, 626.3413, C<sub>37</sub>H<sub>48</sub>N<sub>3</sub>O<sub>4</sub>Si requires 626.3414.  $\nu_{max}$  (film)/cm<sup>-1</sup>: 2931 (C–H), 1455,

1427, 1222 (C–O), 1112 (C–O), 979, 702.  $\delta_{\rm H}$  (400 MHz; CDCl<sub>3</sub>): 1.06 (9 H, s, OSiPh<sub>2</sub>'Bu), 1.25–1.31 (1 H, m, 9'-H<sub>A</sub>), 1.42–1.51 (1 H, m, 11'-H<sub>A</sub>), 1.54–1.62 (3 H, m, 5'-H<sub>A</sub>, 9'-H<sub>B</sub> and 10'-H<sub>B</sub>), 1.70–1.81 (3 H, m, 4'-H<sub>A</sub>, 5'-H<sub>B</sub> and 11'-H<sub>B</sub>), 1.81–1.96 (2 H, m, 3'-H<sub>A</sub> and 10'-H<sub>B</sub>), 2.05–2.18 (2 H, m, 3'-H<sub>B</sub> and 4'-H<sub>B</sub>), 3.08 (2 H, t,  $J_{1",2"}$  6.7, 1"-H), 3.63 (1 H, dd,  $J_{AB}$  10.5 and  $J_{8'-CH_2,8'}$  4.0, 8'-*CH<sub>A</sub>*H<sub>B</sub>O), 3.72 (1 H, dd,  $J_{AB}$  10.5 and  $J_{8'-CH_2,8'}$  4.0, 8'-*CH<sub>A</sub>*H<sub>B</sub>O), 3.72 (1 H, dd,  $J_{AB}$  10.5 and  $J_{8'CH_2,8'}$  6.3, 8'-*CH<sub>A</sub>*H<sub>B</sub>O), 3.79 (2 H, t,  $J_{2",1"}$  6.7, 2"-H), 3.87–3.94 (1 H, m, 8'-H), 4.55 (2 H, s, O*CH*<sub>2</sub>Ph), 6.01 (1 H, dd,  $J_{2'ax,3'ax}$  11.1 and  $J_{2'ax,3'ay}$  2.4, 2'-H<sub>ax</sub>), 7.27–7.34 (5 H, m, O*CH*<sub>2</sub>*Ph*), 7.34–7.43 (6 H, m, O*SiPh*<sub>2</sub>'Bu), 7.54 (1 H, s, 5-H), 7.72–7.75 (4 H, m, O*SiPh*<sub>2</sub>'Bu).  $\delta_{\rm C}$  (75 MHz; CDCl<sub>3</sub>): 18.0 (CH<sub>2</sub>, C-4'), 18.1 (CH<sub>2</sub>, C-10'), 19.2 (C, O*SiPh*<sub>2</sub>'*Bu*), 26.5 (CH<sub>2</sub>, C-9'), 26.6 (CH<sub>2</sub>, C-1''), 26.8 (CH<sub>3</sub>, O*SiPh*<sub>2</sub>'*Bu*), 30.8 (CH<sub>2</sub>, C-3'), 34.5 (CH<sub>2</sub>, C-5'), 34.6 (CH<sub>2</sub>, C-11'), 67.2 (CH<sub>2</sub>, 8'-CH<sub>2</sub>O), 69.1 (CH<sub>2</sub>, C-2''), 71.0 (CH, C-8'), 73.0 (CH<sub>2</sub>, O*CH*<sub>2</sub>*Ph*), 81.0 (CH, C-2'), 98.8 (C, C-6'), 119.9 (CH, C-5), 127.6 (CH, O*SiPh*<sub>2</sub>'*Bu*), 133.6 (C, O*SiPh*<sub>2</sub>'*Bu*), 133.7 (C, O*SiPh*<sub>2</sub>'*Bu*), 135.6 (CH, O*SiPh*<sub>2</sub>'*Bu*), 138.2 (C, O*CH*<sub>2</sub>*Ph*), 144.8 (C, C-4). *m/z* (FAB): 626 (MH<sup>+</sup>, 6%), 423 (C<sub>26</sub>H<sub>35</sub>O<sub>3</sub>Si, 55), 405 (31), 386 (M – OSiPh\_2'Bu, 8), 239 (SiPh<sub>2</sub>'*Bu*, 12), 207 (54), 204 (51), 197 (35), 154 (19), 135 (100), 105 (22), 91 (83).

# 1-{(2'S\*,6'S\*,8'S\*)-8'-(*tert*-Butyldiphenylsilyloxymethyl)-1',7'-dioxaspiro[5.5]undecan-2'-yl}-4-hydroxymethyl-1*H*-1,2,3-triazole (14b)

Method A: The *title compound* **14b** (13.9 mg, 83%) was prepared as a pale yellow oil from azide **5a** (15.0 mg, 32.2 µmol), prop-2-yn-1-ol (**6b**, 100 µL) and CuI•[P(OEt)<sub>3</sub>] (1.15 mg, 3.22 µmol) in toluene (500 µL) using the general procedure (method A) described above. Purification was carried out by flash chromatography using hexane–EtOAc (9:1 to 3:2) as eluent. HRMS (FAB): found MH<sup>+</sup>, 522.2797, C<sub>29</sub>H<sub>40</sub>N<sub>3</sub>O<sub>4</sub>Si requires 522.2788.  $v_{max}$  (film)/cm<sup>-1</sup>: 3369 (O–H), 2930 (C–H), 2856, 1428, 1222, 1112 (C–O), 1091 (C–O), 980, 703.  $\delta_{\rm H}$  (300 MHz; CDCl<sub>3</sub>): 1.07 (9 H, s, OSiPh<sub>2</sub>'*Bu*), 1.29–1.36 (1 H, m, 9'-H<sub>A</sub>), 1.41–1.51 (1 H, m, 11'-H<sub>A</sub>), 1.51–1.64 (3 H, m, 5'-H<sub>A</sub>, 9'-H<sub>B</sub> and 10'-H<sub>A</sub>), 1.68–1.87 (5 H, m, 4'-H<sub>A</sub>, 5'-H<sub>B</sub>, 10'-H<sub>B</sub>, 11'-H<sub>B</sub> and OH), 1.87–1.99 (1 H, m, 3'-H<sub>A</sub>), 2.07–2.21 (2 H, m, 3'-H<sub>B</sub> and 4'-H<sub>B</sub>), 3.63 (1 H, dd,  $J_{AB}$  10.5 and  $J_{8'-CH_2,8'}$  4.2, 8'-CH<sub>4</sub>H<sub>B</sub>O), 3.83 (1 H, dd,  $J_{AB}$  10.5 and  $J_{8'-CH_2,8'}$  4.2, 8'-CH<sub>4</sub>H<sub>B</sub>O), 6.03 (1 H, dd,  $J_{2'ax,3'ax}$  11.0 and  $J_{2'ax,3'ax}$  2.4, 2'-H<sub>ax</sub>), 7.34–7.45 (6 H, m, Ph), 7.68 (1 H, s, 5-H), 7.70–7.76 (4 H, m, Ph).  $\delta_{\rm C}$  (75 MHz; CDCl<sub>3</sub>): 18.0 (CH<sub>2</sub>, C-4'), 18.2 (CH<sub>2</sub>, C-10'), 19.2 (C, OSiPh<sub>2</sub>'*Bu*), 26.5 (CH<sub>2</sub>, C-9'), 26.8 (CH<sub>3</sub>, OSiPh<sub>2</sub>'*Bu*), 30.9 (CH<sub>2</sub>, C-3'), 34.5 (CH<sub>2</sub>, C-5'), 34.6 (CH<sub>2</sub>, C-11'), 56.7 (CH<sub>2</sub>, 4-CH<sub>2</sub>OH), 67.1 (CH<sub>2</sub>, 8'-CH<sub>2</sub>O), 71.2 (CH, C-8'), 81.2 (CH, C-2'), 98.9 (C, C-6'), 119.9 (CH, C-5), 127.6 (CH, Ph), 129.6 (CH, Ph), 133.6 (C, Ph), 133.7 (C, Ph), 135.6 (CH, Ph), 135.6 (CH, Ph), 147.2 (C, C-

4). *m/z* (FAB): 522 (MH<sup>+</sup>, 3%), 464 (M – 'Bu, 7), 423 (C<sub>26</sub>H<sub>35</sub>O<sub>3</sub>Si, 82), 365 (11), 239 (SiPh<sub>2</sub>'Bu, 9), 207 (31), 199 (38), 197 (35), 137 (29), 135 (100).

## 1-{(2'S\*,6'S\*,8'S\*)-8'-(*tert*-Butyldiphenylsilyloxymethyl)-1',7'-dioxaspiro[5.5]undecan-2'-yl}-4-phenyl-1*H*-1,2,3-triazole (14c)

Method A: The title compound 14c (14.2 mg, 96%) was prepared as a pale yellow oil from azide 5a (12.0 mg, 25.8 µmol), phenylacetylene (6c, 50.0 µL) and CuI•[P(OEt)<sub>3</sub>] (1.07 mg, 3.00 µmol) in toluene (250 µL) using the general procedure (method A) described above. Purification was carried out by flash chromatography using hexane-EtOAc (99:1 to 19:1) as eluent. HRMS (FAB): found MH<sup>+</sup>, 568.3001,  $C_{34}H_{42}N_3O_3Si$  requires 568.2996.  $v_{max}$  (film)/cm<sup>-1</sup>: 2932 (C–H), 2857, 1428, 1390, 1220, 1112 (C–O), 1074 (C–O), 1024, 979, 702.  $\delta_{\rm H}$  (300 MHz; CDCl<sub>3</sub>): 1.08 (9 H, s, OSiPh<sub>2</sub><sup>t</sup>Bu), 1.27–1.34 (1 H, m, 9'-H<sub>A</sub>), 1.44–1.55 (1 H, m, 11'-H<sub>A</sub>), 1.56–1.65 (3 H, m, 5'-H<sub>A</sub>, 9'-H<sub>B</sub> and 10'-H<sub>A</sub>), 1.73–1.89 (4 H, m, 4'-H<sub>A</sub>, 5'-H<sub>B</sub>, 10'-H<sub>B</sub> and 11'-H<sub>B</sub>), 1.92–2.04 (1 H, m, 3'-H<sub>A</sub>), 2.10–2.26 (2 H, m, 3'-H<sub>B</sub> and 4'-H<sub>B</sub>), 3.65 (1 H, dd, J<sub>AB</sub> 10.5 and J<sub>8'-CH<sub>2,8'</sub> 4.2, 8'-CH<sub>A</sub>H<sub>B</sub>O), 3.74 (1 H, dd, J<sub>AB</sub> 10.5 and J<sub>8'-CH<sub>2,8'</sub> 6.3,</sub></sub> 8'-CH<sub>A</sub>H<sub>B</sub>O), 3.89–3.98 (1 H, m, 8'-H), 6.01 (1 H, dd, J<sub>2'x,3'x</sub> 11.1 and J<sub>2'x,3'm</sub> 2.4, 2'-H<sub>ax</sub>), 7.32–7.47 (9 H, m, OSiPh<sub>2</sub><sup>t</sup>Bu and Ph), 7.72–7.78 (4 H, m, OSiPh<sub>2</sub><sup>t</sup>Bu), 7.84–7.89 (2 H, m, Ph), 7.90 (1 H, s, 5-H). δ<sub>C</sub> (75 MHz; CDCl<sub>3</sub>): 18.0 (CH<sub>2</sub>, C-4'), 18.2 (CH<sub>2</sub>, C-10'), 19.3 (C, OSiPh<sub>2</sub><sup>t</sup>Bu), 26.5 (CH<sub>2</sub>, C-9'), 26.8 (CH<sub>3</sub>, OSiPh<sub>2</sub><sup>t</sup>Bu), 31.1 (CH<sub>2</sub>, C-3'), 34.5 (CH<sub>2</sub>, C-5'), 34.6 (CH<sub>2</sub>, C-11'), 67.2 (CH<sub>2</sub>, 8'-CH<sub>2</sub>O), 71.2 (CH, C-8'), 81.2 (CH, C-2'), 99.0 (C, C-6'), 117.7 (CH, C-5), 125.8 (CH, Ph), 127.7 (CH, OSiPh2'Bu), 128.1 (CH, Ph), 128.8 (CH, Ph), 129.6 (CH, OSiPh2'Bu), 129.6 (CH, OSiPh2'Bu), 130.8 (C, Ph), 133.7 (C, OSiPh<sub>2</sub><sup>t</sup>Bu), 135.6 (CH, OSiPh<sub>2</sub><sup>t</sup>Bu), 135.7 (CH, OSiPh<sub>2</sub><sup>t</sup>Bu), 147.5 (C, C-4). m/z (FAB): 568 (MH<sup>+</sup>, 3%), 510 (M – <sup>*t*</sup>Bu, 7), 423 (C<sub>26</sub>H<sub>35</sub>O<sub>3</sub>Si, 45), 239 (SiPh<sub>2</sub><sup>*t*</sup>Bu, 8), 207 (38), 199 (31), 197 (37), 137 (21), 135 (100), 121 (16), 91 (18).

## Ethyl 1-{(2'*S*\*,6'*S*\*,8'*S*\*)-8'-(*tert*-butyldiphenylsilyloxymethyl)-1',7'dioxaspiro[5.5]undecan-2'-yl}-1*H*-1,2,3-triazole-4-carboxylate (14d)

Method A: The *title compound* **14d** (9.00 mg, 84%) was prepared as a pale yellow oil from azide **5a** (9.00 mg, 19.3 µmol), ethyl propiolate (**6d**, 50.0 µL) and CuI•[P(OEt)<sub>3</sub>] (0.71 mg, 2.00 µmol) in toluene (250 µL) using the general procedure (method A) described above. Purification was carried out by flash chromatography using hexane–EtOAc (19:1 to 9:1) as eluent. HRMS (FAB): found MH<sup>+</sup>, 564.2892, C<sub>31</sub>H<sub>42</sub>N<sub>3</sub>O<sub>5</sub>Si requires 564.2894.  $v_{max}$  (film)/cm<sup>-1</sup>: 2932 (C–H), 1742 (C=O), 1428, 1221 (C–O), 1113 (C–O), 980, 703.  $\delta_{\rm H}$  (300 MHz; CDCl<sub>3</sub>): 1.06 (9 H, s, OSiPh<sub>2</sub><sup>*i*</sup>Bu), 1.28–1.35 (1 H, m, 9'-H<sub>A</sub>), 1.42 (3 H, t,  $J_{\rm CH_3,CH_2}$  7.1, OCH<sub>2</sub>*CH*<sub>3</sub>), 1.46–1.55 (1 H, m, 11'-H<sub>A</sub>), 1.55–1.65 (3 H, m, 5'-H<sub>A</sub>, 9'-H<sub>B</sub> and 10'-H<sub>A</sub>), 1.69–1.92 (5 H, m, 3'-H<sub>A</sub>, 4'-H<sub>A</sub>, 5'-H<sub>B</sub>, 10'-H<sub>B</sub> and 11'-H<sub>B</sub>), 2.11–2.23 (2 H, m, 3'-H<sub>B</sub> and

4'-H<sub>B</sub>), 3.62 (1 H, dd,  $J_{AB}$  10.5 and  $J_{8'-CH_2,8'}$  4.2, 8'-*CH*<sub>A</sub>H<sub>B</sub>O), 3.72 (1 H, dd,  $J_{AB}$  10.5 and  $J_{8-CH_2,8'}$  6.3, 8'-CH<sub>A</sub>H<sub>B</sub>O), 3.82–3.89 (1 H, m, 8'-H), 4.45 (2 H, t,  $J_{CH_2,CH_3}$  7.1, O*CH*<sub>2</sub>CH<sub>3</sub>), 6.07 (1 H, dd,  $J_{2'ax,3'ax}$  10.9 and  $J_{2'ax,3'eq}$  2.2, 2'-H<sub>ax</sub>), 7.34–7.44 (6 H, m, Ph), 7.69–7.75 (4 H, m, Ph), 8.25 (1 H, s, 5-H). & (75 MHz; CDCl<sub>3</sub>): 14.1 (CH<sub>3</sub>, OCH<sub>2</sub>*CH*<sub>3</sub>), 17.8 (CH<sub>2</sub>, C-4'), 18.1 (CH<sub>2</sub>, C-10'), 19.2 (C, OSiPh<sub>2</sub><sup>*i*</sup>*Bu*), 26.4 (CH<sub>2</sub>, C-9'), 26.8 (CH<sub>3</sub>, OSiPh<sub>2</sub><sup>*i*</sup>*Bu*), 31.2 (CH<sub>2</sub>, C-3'), 34.4 (CH<sub>2</sub>, C-5'), 34.5 (CH<sub>2</sub>, C-11'), 61.2 (CH<sub>2</sub>, O*CH*<sub>2</sub>CH<sub>3</sub>), 67.1 (CH<sub>2</sub>, 8'-CH<sub>2</sub>O), 71.3 (CH, C-8'), 81.6 (CH, C-2'), 99.2 (C, C-6'), 125.7 (CH, C-5), 127.6 (CH, Ph), 129.6 (CH, Ph), 133.6 (C, Ph), 133.6 (C, Ph), 135.6 (CH, Ph), 135.6 (CH, Ph), 140.0 (C, C-4), 160.9 (C, C=O). *m*/*z* (FAB): 564 (MH<sup>+</sup>, 0.5%), 518 (M – OEt, 2), 506 (M – <sup>*i*</sup>Bu, 5), 486 (M – Ph, 2), 423 (C<sub>26</sub>H<sub>35</sub>O<sub>3</sub>Si, 69), 365 (18), 239 (SiPh<sub>2</sub><sup>*i*</sup>Bu, 10), 207 (49), 199 (34), 197 (32), 135 (100), 121 (22).

# Dimethyl 1-{(2'S\*,6'S\*,8'S\*)-8'-(*tert*-butyldiphenylsilyloxymethyl)-1',7'dioxaspiro[5.5]undecan-2'-yl}-1*H*-1,2,3-triazole-4,5-dicarboxylate (14e)

Method B: The *title compound* 14e (8.30 mg, 78%) was prepared as a pale yellow oil from azide 5a (8.20 mg, 17.6  $\mu$ mol) and dimethyl acetylenedicarboxylate (6e, 100  $\mu$ L) in toluene (500  $\mu$ L) using the general procedure (method B) described above. Purification was carried out by flash chromatography using hexane-EtOAc (19:1 to 9:1) as eluent. HRMS (FAB): found  $[M - {}^{t}Bu]^{+}$ , 550.2010, C<sub>28</sub>H<sub>32</sub>N<sub>3</sub>O<sub>7</sub>Si requires 550.2010.  $\nu_{max}$  (film)/cm<sup>-1</sup>: 2929 (C–H), 1741 (C=O), 1428, 1098 (C–O), 703.  $\delta_{\rm H}$  (400 MHz; CDCl<sub>3</sub>): 1.07 (9 H, s, OSiPh<sub>2</sub><sup>t</sup>Bu), 1.27–1.33 (1 H, m, 9'-H<sub>A</sub>), 1.41–1.51 (1 H, m, 11'-H<sub>A</sub>), 1.54–1.80 (7 H, m, 4'-H<sub>A</sub>, 5'-H<sub>A</sub>, 5'-H<sub>B</sub>, 9'-H<sub>B</sub>, 10'-H<sub>A</sub>, 10'-H<sub>B</sub> and 11'-H<sub>B</sub>), 2.03– 2.27 (3 H, m, 3'-H<sub>A</sub>, 3'-H<sub>B</sub> and 4'-H<sub>B</sub>), 3.60 (1 H, dd, J<sub>AB</sub> 10.3 and J<sub>8'-CH2,8'</sub> 4.8, 8'-CH<sub>A</sub>H<sub>B</sub>O), 3.71 (1 H, dd, J<sub>AB</sub> 10.3 and J<sub>8'-CH2.8'</sub> 5.8, 8'-CH<sub>A</sub>H<sub>B</sub>O), 3.77–3.83 (1 H, m, 8'-H), 3.96 (6 H, s, 2 x OMe), 6.18 (1 H, dd,  $J_{2'_{ax},3'_{ax}}$  10.6 and  $J_{2'_{ax},3'_{eq}}$  3.0, 2'-H<sub>ax</sub>), 7.34–7.44 (6 H, m, Ph), 7.68–7.74 (4 H, m, Ph).  $\delta_{C}$  (100 MHz; CDCl<sub>3</sub>): 17.5 (CH<sub>2</sub>, C-4'), 17.8 (CH<sub>2</sub>, C-10'), 19.3 (C, OSiPh<sub>2</sub><sup>t</sup>Bu), 26.6 (CH<sub>2</sub>, C-9'), 26.8 (CH<sub>3</sub>, OSiPh<sub>2</sub><sup>'</sup>Bu), 30.4 (CH<sub>2</sub>, C-3'), 34.4 (CH<sub>2</sub>, C-5'), 34.7 (CH<sub>2</sub>, C-11'), 52.6 (CH<sub>3</sub>, OMe), 53.4 (CH<sub>3</sub>, OMe), 66.9 (CH<sub>2</sub>, 8'-CH<sub>2</sub>O), 71.0 (CH, C-8'), 82.8 (CH, C-2'), 99.4 (C, C-6'), 127.6 (CH, Ph), 129.6 (CH, Ph), 129.6 (CH, Ph), 131.8 (C, C-5), 133.5 (C, Ph), 133.6 (C, Ph), 135.6 (CH, Ph), 135.6 (CH, Ph), 138.0 (C, C-4), 160.1 (C, C=O), 160.3 (C, C=O). m/z (FAB): 550 ([M – <sup>t</sup>Bu]<sup>+</sup>, 2%), 423 (C<sub>26</sub>H<sub>35</sub>O<sub>3</sub>Si, 52), 207 (42), 199 (35), 197 (33), 137 (23), 135 (100).

## 1-{(2'S\*,6'S\*,8'S\*)-8'-(*tert*-Butyldiphenylsilyloxymethyl)-1',7'-dioxaspiro[5.5]undecan-2'-yl}-4-(trimethylsilyl)-1*H*-1,2,3-triazole (14f)

Method C: The *title compound* **14f** (7.80 mg, 64%) was prepared as a pale yellow oil from azide 5a (10.1 mg, 21.6  $\mu$ mmol) and trimethylsilylacetylene (6f, 2 x 100  $\mu$ L) in toluene (500  $\mu$ L) using the general procedure (method C) described above. Purification was carried out by flash chromatography using hexane-EtOAc (99:1 to 9:1) as eluent. Unreacted azide 5a (3.60 mg, 36%) was also recovered. HRMS (FAB): found MH<sup>+</sup>, 564.3079,  $C_{31}H_{46}N_3O_3Si_2$  requires 564.3078.  $\nu_{max}$ (film)/cm<sup>-1</sup>: 2951 (C–H), 1428, 1249 (C–O), 1113 (C–O), 980, 842, 702.  $\delta_{\rm H}$  (300 MHz; CDCl<sub>3</sub>): 0.34 (9 H, s, OSiMe<sub>3</sub>), 1.07 (9 H, s, OSiPh<sub>2</sub><sup>t</sup>Bu), 1.26–1.34 (1 H, m, 9'-H<sub>A</sub>), 1.40–1.53 (1 H, m, 11'-H<sub>A</sub>), 1.53–1.64 (3 H, m, 5'-H<sub>A</sub>, 9'-H<sub>B</sub> and 10'-H<sub>A</sub>), 1.70–1.80 (3 H, m, 4'-H<sub>A</sub>, 5'-H<sub>B</sub> and 11'-H<sub>B</sub>), 1.80–1.99 (2 H, m, 3'-H<sub>A</sub> and 10'-H<sub>B</sub>), 2.06–2.25 (2 H, m, 3'-H<sub>B</sub> and 4'-H<sub>B</sub>), 3.63 (1 H, dd, J<sub>AB</sub> 10.5 and J<sub>8'</sub>. <sub>CH2.8'</sub> 4.2, 8'-CH<sub>A</sub>H<sub>B</sub>O), 3.72 (1 H, dd, J<sub>AB</sub> 10.5 and J<sub>8'-CH2.8'</sub> 6.3, 8'-CH<sub>A</sub>H<sub>B</sub>O), 3.88–3.96 (1 H, m, 8'-H), 6.11 (1 H, dd, J<sub>2'ax,3'ax</sub> 11.0 and J<sub>2'ax,3'eq</sub> 2.5, 2'-H<sub>ax</sub>), 7.35–7.43 (6 H, m, Ph), 7.66 (1 H, s, 5-H), 7.70–7.76 (4 H, m, Ph). δ<sub>C</sub> (75 MHz; CDCl<sub>3</sub>): -1.1 (CH<sub>3</sub>, SiMe<sub>3</sub>), 18.1 (CH<sub>2</sub>, C-4'), 18.2 (CH<sub>2</sub>, C-10'), 19.2 (C, OSiPh<sub>2</sub><sup>t</sup>Bu), 26.5 (CH<sub>2</sub>, C-9'), 26.8 (CH<sub>3</sub>, OSiPh<sub>2</sub><sup>t</sup>Bu), 31.2 (CH<sub>2</sub>, C-3'), 34.6 (CH<sub>2</sub>, C-5'), 34.7 (CH<sub>2</sub>, C-11'), 67.2 (CH<sub>2</sub>, 8'-CH<sub>2</sub>O), 71.1 (CH, C-8'), 80.7 (CH, C-2'), 98.9 (C, C-6'), 126.9 (CH, C-5), 127.6 (CH, Ph), 129.6 (CH, Ph), 129.6 (CH, Ph), 133.7 (C, Ph), 135.6 (CH, Ph), 135.7 (CH, Ph), 146.1 (C, C-4). *m/z* (FAB): 564 (MH<sup>+</sup>, 4%), 423 (C<sub>26</sub>H<sub>35</sub>O<sub>3</sub>Si, 74), 405 (15), 239 (SiPh<sub>2</sub><sup>*t*</sup>Bu, 10), 207 (37), 197 (36), 142 (23), 135 (100), 73 (52).

## Ethyl 1-{(2'S\*,6'S\*,8'S\*)-8'-(*tert*-butyldiphenylsilyloxymethyl)-1',7'dioxaspiro[5.5]undecan-2'-yl}-4-(trimethylsilyl)-1*H*-1,2,3-triazole-5-carboxylate (14g)

Method C: The *title compound* **14g** (9.10 mg, 84%) was prepared as a pale yellow oil from azide **5a** (8.00 mg, 17.2 µmol) and ethyl 3-(trimethylsilyl)propiolate (**6g**, 2 x 50.0 µL) in toluene (500 µL) using the general procedure (method C) described above. Purification was carried out by flash chromatography using hexane–EtOAc (97:3, 19:1 to 9:1) as eluent. HRMS (FAB): found MH<sup>+</sup>, 636.3293, C<sub>34</sub>H<sub>50</sub>N<sub>3</sub>O<sub>5</sub>Si<sub>2</sub> requires 636.3289.  $v_{max}$  (film)/cm<sup>-1</sup>: 2955 (C–H), 2857, 1728 (C=O), 1428, 1192, 1112 (C–O), 1079 (C–O), 847, 703.  $\delta_{\rm H}$  (300 MHz; CDCl<sub>3</sub>): 0.39 (9 H, s, SiMe<sub>3</sub>), 1.08 (9 H, s, OSiPh<sub>2</sub>'Bu), 1.30–1.40 (1 H, m, 9'-H<sub>A</sub>), 1.36 (3 H, t,  $J_{\rm CH_3,CH_2}$  7.2, OCH<sub>2</sub>CH<sub>3</sub>), 1.41–1.49 (1 H, m, 11'-H<sub>A</sub>), 1.50–1.61(1 H, m, 10'-H<sub>A</sub>), 1.62–1.84 (6 H, m, 4'-H<sub>A</sub>, 5'-H<sub>A</sub>, 5'-H<sub>B</sub>, 9'-H<sub>B</sub>, 10'-H<sub>B</sub> and 11'-H<sub>B</sub>), 1.94–2.03 (1 H, m, 3'-H<sub>A</sub>), 2.03–2.21 (1 H, m, 4'-H<sub>B</sub>), 2.51–2.66 (1 H, m, 3'-H<sub>B</sub>), 3.66 (1 H, dd,  $J_{AB}$  10.0 and  $J_{8'-CH_2,8'}$  5.6, 8'-CH<sub>A</sub>H<sub>B</sub>O), 3.83 (1 H, dd,  $J_{AB}$  10.0 and  $J_{8'-CH_2,8'}$  4.9, 8'-CH<sub>A</sub>H<sub>B</sub>O), 4.02–4.11 (1 H, m, 8'-H), 4.28–4.44 (2 H, m, OCH<sub>2</sub>CH<sub>3</sub>), 6.65 (1 H, dd,  $J_{2'ax,3'ax}$  11.3 and  $J_{2'ax,3'eq}$  2.6, 2'-H<sub>ax</sub>), 7.35–7.46 (6 H, m, Ph), 7.74–7.80 (4 H, m, Ph).  $\delta_{\rm C}$  (75 MHz; CDCl<sub>3</sub>): -1.1 (CH<sub>3</sub>, SiMe<sub>3</sub>), 14.2 (CH<sub>3</sub>,

OCH<sub>2</sub>*C*H<sub>3</sub>), 18.1 (CH<sub>2</sub>, C-4' and C-10'), 19.3 (C, OSiPh<sub>2</sub><sup>*i*</sup>*Bu*), 26.8 (CH<sub>3</sub>, OSiPh<sub>2</sub><sup>*i*</sup>*Bu*), 27.1 (CH<sub>2</sub>, C-9'), 29.7 (CH<sub>2</sub>, C-3'), 34.8 (CH<sub>2</sub>, C-5'), 35.0 (CH<sub>2</sub>, C-11'), 61.8 (CH<sub>2</sub>, OCH<sub>2</sub>CH<sub>3</sub>), 67.1 (CH<sub>2</sub>, 8'-CH<sub>2</sub>O), 70.4 (CH, C-8'), 80.3 (CH, C-2'), 99.0 (C, C-6'), 127.5 (CH, Ph), 129.5 (CH, Ph), 129.5 (CH, Ph), 133.1 (C, C-5), 133.8 (C, Ph), 134.0 (C, Ph), 135.7 (CH, Ph), 135.7 (CH, Ph), 150.1 (C, C-4), 159.8 (C, C=O). *m/z* (FAB): 636 (MH<sup>+</sup>, 1%), 578 (M – <sup>*i*</sup>Bu, 3), 558 (M – Ph, 1), 423 (C<sub>26</sub>H<sub>35</sub>O<sub>3</sub>Si, 39), 214 (22), 207 (27), 199 (33), 197 (38), 135 (100), 73 (45).

# Synthesis of triazole 7a-g

#### General procedures for deprotection of silyl protected spiroacetal-triazoles 14

#### Method A: Desilylation using TBAF

To a solution of TBDPS-protected triazole 14 in anhydrous THF (1.0 mL) under an atmosphere of argon at room temperature was added activated molecular sieves (0.20 g) and TBAF solution (1.0 mol L<sup>-1</sup> in THF, 2.0–10 equiv.). After 1–3 h, saturated NH<sub>4</sub>Cl solution (1 mL) was added. The aqueous phase was extracted with Et<sub>2</sub>O (3 x 2 mL) and the combined organic extracts were concentrated *in vacuo*. Purification by flash chromatography using the appropriate eluent yielded hydroxymethyl spiroacetal-triazole 7.

#### Method B: Desilylation using HF•pyridine

To a solution of TBDPS-protected triazole 14 in anhydrous THF (1.0–2.0 mL) in a plastic vial under an atmosphere of argon was added HF•pyridine (1.5–3.4  $\mu$ L per micromole of triazole) and the mixture was stirred at room temperature. If the desilylation was not complete within 18 h (TLC), a second portion of HF•pyridine (1.3–2.0  $\mu$ L per micromole of triazole) was added and the mixture was stirred at room temperature for another 18 h. Saturated NaHCO<sub>3</sub> solution (4 mL) was added dropwise. The aqueous phase was extracted with Et<sub>2</sub>O (4 x 4 mL) and the combined organic extracts were concentrated *in vacuo*. Purification by flash chromatography using the appropriate eluent yielded hydroxymethyl spiroacetal-triazole 7.

#### Method C: Desilylation using 3HF•NEt<sub>3</sub>

A solution of TBDPS-protected triazole 14 and  $3HF \cdot NEt_3$  (2.0–3.0 µL per micromole of triazole) in anhydrous THF (300 µL–1.0 mL) was stirred at room temperature under an atmosphere of argon. If the desilylation was not complete within 18 h (TLC), a second portion of  $3HF \cdot NEt_3$  (2.0–2.5 µL per micromole of triazole) was added and the mixture was stirred at room temperature for another 18 h. Saturated NaHCO<sub>3</sub> solution (4 mL) was added dropwise. The aqueous phase was extracted with  $Et_2O$  (4 x 4 mL) and the combined organic extracts were concentrated *in vacuo*. Purification by flash chromatography using the appropriate eluent yielded hydroxymethyl spiroacetal-triazole 7.

#### Method D: Desilylation using 3HF•NEt<sub>3</sub> and buffered with NEt<sub>3</sub>

A solution of TBDPS-protected triazole 14,  $3HF \cdot NEt_3$  (2.0 µL per micromole of triazole) and NEt<sub>3</sub> (2.5 µL per micromole of triazole) in anhydrous THF (700 µL) was stirred at 40 °C for 48 h under an atmosphere of argon. A second portion of  $3HF \cdot NEt_3$  (1.0 µL micromole of triazole) and NEt<sub>3</sub> (1.3 µL per micromole of triazole) were added and the mixture was stirred at 40 °C for 18 h. Saturated NaHCO<sub>3</sub> solution (2 mL) was added dropwise. The aqueous phase was extracted with EtOAc (3 x 3 mL) and the combined organic extracts were concentrated *in vacuo*. Purification by flash chromatography using hexane–EtOAc as eluent yielded hydroxymethyl spiroacetal-triazole 7.

## 4-[2''-(Benzyloxy)ethyl]-1-{(2'S\*,6'S\*,8'S\*)-8'-(hydroxymethyl)-1',7'dioxaspiro[5.5]undecan-2'-yl}-1*H*-1,2,3-triazole (7a)

Method C: The *title compound* **7a** (13.7 mg, 99%) was prepared as a pale yellow oil from TBDPS-protected triazole **14a** (22.3 mg, 35.6 µmol) and 3HF•NEt<sub>3</sub> (2 x 72.0 µL) in anhydrous THF (1.0 mL) using the general procedure (method C) described above. Purification was carried out by flash chromatography using hexane–EtOAc (9:1, 1:1 to 0:1) as eluent. HRMS (FAB): found MH<sup>+</sup>, 388.2244, C<sub>21</sub>H<sub>30</sub>N<sub>3</sub>O<sub>4</sub> requires 388.2236.  $\nu_{max}$  (film)/cm<sup>-1</sup>: 3400 (O–H), 2942 (C–H), 2870, 1455, 1387, 1223 (C–O), 1099 (C–O), 1048, 980, 737.  $\delta_{\rm H}$  (400 MHz; CDCl<sub>3</sub>): 1.33–1.42 (1 H, m, 9'-H<sub>A</sub>), 1.42–1.52 (2 H, m, 9'-H<sub>B</sub> and 11'-H<sub>A</sub>), 1.53–1.62 (2 H, m, 5'-H<sub>A</sub> and 10'-H<sub>A</sub>), 1.72–1.87 (5 H, m, 4'-H<sub>A</sub>, 5'-H<sub>B</sub>, 10'-H<sub>B</sub>, 11'-H<sub>B</sub> and OH), 1.87–2.04 (1 H, m, 3'-H<sub>A</sub>), 2.06–2.16 (2 H, m, 3'-H<sub>B</sub> and 4'-H<sub>B</sub>), 3.06 (2 H, t,  $J_{1'',2''}$  6.6, 1''-H), 3.56 (1 H, dd,  $J_{AB}$  11.6 and  $J_{8'CH_2,8'}$  6.2, 8'-*CH*<sub>4</sub>H<sub>B</sub>O), 3.69 (1 H, dd,  $J_{AB}$  11.6 and  $J_{8'CH_2,8'}$  6.2, 8'-*CH*<sub>4</sub>H<sub>B</sub>O), 3.69 (1 H, dd,  $J_{AB}$  11.6 and  $J_{8'CH_2,8'}$  6.2, 8'-*CH*<sub>4</sub>H<sub>B</sub>O), 3.69 (1 H, dd,  $J_{AB}$  11.6 and  $J_{8'CH_2,8'}$  6.2, 8'-*CH*<sub>4</sub>H<sub>B</sub>O), 3.69 (1 H, dd,  $J_{AB}$  11.6 cm  $J_{2'ax,3'eq}$  2.3, 2'-H<sub>ax</sub>), 7.27–7.36 (5 H, m, Ph).  $\delta_{\rm C}$  (100 MHz; CDCl<sub>3</sub>): 17.9 (CH<sub>2</sub>, C-10'), 18.1 (CH<sub>2</sub>, C-4'), 26.0 (CH<sub>2</sub>, C-9'), 26.6 (CH<sub>2</sub>, C-1''), 30.8 (CH<sub>2</sub>, C-3'),

34.4 (CH<sub>2</sub>, C-5'), 34.7 (CH<sub>2</sub>, C-11'), 66.0 (CH<sub>2</sub>, 8'-CH<sub>2</sub>O), 69.1 (CH<sub>2</sub>, C-2"), 70.7 (CH, C-8'), 73.0 (CH<sub>2</sub>, OCH<sub>2</sub>Ph), 81.0 (CH, C-2'), 98.9 (C, C-6'), 119.9 (CH, C-5), 127.6 (CH, Ph), 127.7 (CH, Ph), 128.4 (CH, Ph), 138.2 (C, Ph), 145.0 (C, C-4). *m/z* (FAB): 388 (MH<sup>+</sup>, 8%), 204 (100), 186 (87), 185 (C<sub>10</sub>H<sub>17</sub>O<sub>3</sub>, 45), 121 (18), 99 (23), 91 (51).

## 1-{(2'*S*\*,6'*S*\*,8'*S*\*)-8'-(Hydroxymethyl)-1',7'-dioxaspiro[5.5]undecan-2-yl}-4hydroxymethyl-1*H*-1,2,3-triazole (7b)

Method B: The *title compound* **7b** (4.80 mg, 71%) was prepared as a pale yellow oil from TBDPS-protected triazole **14b** (12.5 mg, 24.0 µmol) and HF•pyridine (60.0 µL) in anhydrous THF (1.5 mL) using the general procedure (method B) described above. Purification was carried out by flash chromatography using hexane–Et<sub>2</sub>O–MeOH (4:1:0, 0:1:0 to 0:19:1) as eluent. HRMS (FAB): found MH<sup>+</sup>, 284.1618, C<sub>13</sub>H<sub>22</sub>N<sub>3</sub>O<sub>4</sub> requires 284.1610.  $v_{max}$  (film)/cm<sup>-1</sup>: 3375 (O–H), 2933 (C–H), 2872, 1456, 1440, 1223 (C–O), 1099 (C–O), 1047, 1017, 979.  $\delta_{\rm H}$  (300 MHz; CDCl<sub>3</sub>): 1.33–1.43 (1 H, m, 9'-H<sub>A</sub>), 1.46–1.64 (4 H, m, 5'-H<sub>A</sub>, 9'-H<sub>B</sub>, 10'-H<sub>A</sub> and 11'-H<sub>A</sub>), 1.70–1.95 (5 H, m, 3'-H<sub>A</sub>, 4'-H<sub>A</sub>, 5'-H<sub>B</sub>, 10'-H<sub>B</sub> and 11'-H<sub>B</sub>), 2.05–2.21 (3 H, m, 3'-H<sub>B</sub>, 4'-H<sub>B</sub> and OH), 2.46 (1 H, br s, OH), 3.57 (1 H, dd,  $J_{AB}$  11.6 and  $J_{8'-CH_2,8'}$  6.3, 8'-CH<sub>A</sub>H<sub>B</sub>O), 3.69 (1 H, dd,  $J_{AB}$  11.6 and  $J_{8'-CH_2,8'}$  3.3, 8'-CH<sub>A</sub>H<sub>B</sub>O), 3.82–3.90 (1 H, m, 8'-H), 4.81 (2 H, s, 4-CH<sub>2</sub>OH), 5.97 (1 H, dd,  $J_{2'ax,3'ax}$  11.0 and  $J_{2'ax,3'cq}$  2.3, 2'-H<sub>ax</sub>), 7.74 (1 H, s, 5-H).  $\delta_{\rm C}$  (100 MHz; CDCl<sub>3</sub>): 17.9 (CH<sub>2</sub>, C-10'), 18.0 (CH<sub>2</sub>, C-4'), 26.0 (CH<sub>2</sub>, C-9'), 30.8 (CH<sub>2</sub>, C-3'), 34.4 (CH<sub>2</sub>, C-5'), 34.6 (CH<sub>2</sub>, C-11'), 56.6 (CH<sub>2</sub>, 4-CH<sub>2</sub>OH), 66.0 (CH<sub>2</sub>, 8'-CH<sub>2</sub>O), 70.8 (CH, C-8'), 81.2 (CH, C-2'), 99.0 (C, C-6'), 119.9 (CH, C-5), 147.4 (C, C-4). *m/z* (FAB): 284 (MH<sup>+</sup>, 12%), 185 (C<sub>10</sub>H<sub>7</sub>O<sub>3</sub>, 45), 155 (40), 149 (37), 138 (52), 137 (100), 120 (20), 91 (26).

# 1-{(2'S\*,6'S\*,8'S\*)-8'-(Hydroxymethyl)-1',7'-dioxaspiro[5.5]undecan-2'-yl}-4-phenyl-1*H*-1,2,3-triazole (7c)

Method A: The *title compound* **7c** (7.10 mg, 81%) was prepared as a pale yellow oil from TBDPS-protected triazole **14c** (15.0 mg, 26.4 µmol) and TBAF solution (264 µL, 264 µmol) in anhydrous THF (1.0 mL) using the general procedure (method A) described above. Purification was carried out by flash chromatography using hexane–EtOAc (9:1 to 7:3) as eluent. HRMS (EI): found  $M^{+\bullet}$ , 329.1735,  $C_{18}H_{23}N_3O_3$  requires 329.1739.  $\nu_{max}$  (film)/cm<sup>-1</sup>: 3389 (O–H), 2944 (C–H), 2873, 1438, 1391, 1234, 1202 (C–O), 1076 (C–O), 1046, 1019, 978, 766, 695.  $\delta_{H}$  (300 MHz; CDCl<sub>3</sub>): 1.39–1.47 (1 H, m, 9'-H<sub>A</sub>), 1.47–1.68 (4 H, m, 5'-H<sub>A</sub>, 9'-H<sub>B</sub>, 10'-H<sub>A</sub> and 11'-H<sub>A</sub>), 1.74–1.97 (4 H, m, 4'-H<sub>A</sub>, 5'-H<sub>B</sub>, 10'-H<sub>B</sub> and 11'-H<sub>B</sub>), 1.98–2.11 (2 H, m, 3'-H<sub>A</sub> and OH), 2.11–2.26 (2 H, m, 3'-H<sub>B</sub> and 4'-H<sub>B</sub>), 3.57–3.67 (1 H, m, 8'-CH<sub>A</sub>H<sub>B</sub>O), 3.72 (1 H, d,  $J_{AB}$  11.3, 8'-CH<sub>A</sub>H<sub>B</sub>O), 3.86–3.95 (1 H, m, 8'-H), 6.03 (1 H,

dd,  $J_{2'_{ax},3'_{ax}}$  11.0 and  $J_{2'_{ax},3'_{eq}}$  2.4, 2'-H<sub>ax</sub>), 7.30–7.36 (1 H, m, Ph), 7.40–7.46 (2 H, m, Ph), 7.84–7.88 (2 H, m, Ph), 7.95 (1 H, s, 5-H).  $\delta_{C}$  (100 MHz; CDCl<sub>3</sub>): 17.9 (CH<sub>2</sub>, C-10'), 18.1 (CH<sub>2</sub>, C-4'), 26.0 (CH<sub>2</sub>, C-9'), 31.0 (CH<sub>2</sub>, C-3'), 34.4 (CH<sub>2</sub>, C-5'), 34.7 (CH<sub>2</sub>, C-11'), 66.0 (CH<sub>2</sub>, 8'-CH<sub>2</sub>O), 70.8 (CH, C-8'), 81.3 (CH, C-2'), 99.1 (C, C-6'), 117.7 (CH, C-5), 125.8 (CH, Ph), 128.1 (CH, Ph), 128.8 (CH, Ph), 130.6 (C, Ph), 147.6 (C, C-4). *m/z* (EI): 329 (M<sup>+•</sup>, 4%), 298 (M – CH<sub>2</sub>OH, 2), 185 (C<sub>10</sub>H<sub>17</sub>O<sub>3</sub>, 55), 145 (100), 128 (15), 121 (22), 117 (18), 99 (36), 71 (25), 57 (15), 55 (29), 43 (15), 41 (26).

# Ethyl 1-{(2'*S*\*,6'*S*\*,8'*S*\*)-8'-(hydroxymethyl)-1',7'-dioxaspiro[5.5]undecan-2'-yl}-1*H*-1,2,3-triazole-4-carboxylate (7d)

Method B: The *title compound* **7d** (3.50 mg, 70%) was prepared as a pale yellow oil from TBDPS-protected triazole **14d** (8.70 mg, 15.4 µmol) and HF•pyridine (2 x 50.0 µL) in anhydrous THF (1.0 mL) using the general procedure (method B) described above. Purification was carried out by flash chromatography using hexane–EtOAc (9:1 to 1:4) as eluent. HRMS (EI): found M<sup>+•</sup>, 325.1638,  $C_{15}H_{23}N_3O_5$  requires 325.1638.  $v_{max}$  (film)/cm<sup>-1</sup>: 3412 (O–H), 2941 (C–H), 1733 (C=O), 1376, 1222 (C–O), 1044 (C–O), 980.  $\delta_{\rm H}$  (300 MHz; CDCl<sub>3</sub>): 1.38–1.45 (1 H, m, 9'-H<sub>A</sub>), 1.42 (3 H, t, *J*<sub>CH<sub>3</sub>,CH<sub>2</sub> 7.1, OCH<sub>2</sub>*CH*<sub>3</sub>), 1.48–1.58 (2 H, m, 9'-H<sub>B</sub> and 11'-H<sub>A</sub>), 1.58–1.66 (2 H, m, 5'-H<sub>A</sub> and 10'-H<sub>A</sub>), 1.73–1.94 (6 H, m, 3'-H<sub>A</sub>, 4'-H<sub>A</sub>, 5'-H<sub>B</sub>, 10'-H<sub>B</sub> and 11'-H<sub>A</sub>), 1.59–2.17 (1 H, m, 4'-H<sub>B</sub>), 2.17–2.28 (1 H, m, 3'-H<sub>B</sub>), 3.52–3.63 (1 H, m, 8'-*CH*<sub>4</sub>H<sub>B</sub>O), 3.63–3.76 (1 H, m, 8'-*CH*<sub>A</sub>*H*<sub>B</sub>O), 3.79–3.88 (1 H, m, 8'-H), 4.44 (2 H, t, *J*<sub>CH<sub>2</sub>,CH<sub>3</sub>): 14.3 (CH<sub>3</sub>, OCH<sub>2</sub>*CH*<sub>3</sub>), 17.8 (CH<sub>2</sub>, C-10'), 17.9 (CH<sub>2</sub>, C-4'), 25.9 (CH<sub>2</sub>, C-9'), 31.2 (CH<sub>2</sub>, C-3'), 34.4 (CH<sub>2</sub>, C-5'), 34.6 (CH<sub>2</sub>, C-11'), 61.3 (CH<sub>2</sub>, OC*H*<sub>2</sub>CH<sub>3</sub>), 65.9 (CH<sub>2</sub>, 8'-CH<sub>2</sub>O), 70.9 (CH, C-8'), 81.7 (CH, C-2'), 99.3 (C, C-6'), 125.7 (CH, C-5), 140.2 (C, C-4), 160.8 (C, C=O). *m/z* (EI): 325 (M<sup>+•</sup>, 5%), 294 (M – CH<sub>2</sub>OH, 2), 280 (M – OEt, 3), 252 (M – CO<sub>2</sub>Et, 2), 185 (C<sub>10</sub>H<sub>17</sub>O<sub>3</sub>, 43), 156 (60), 128 (100), 114 (25), 99 (69), 96 (67), 70 (49), 55 (47), 41 (50).</sub></sub>

## Dimethyl 1-{(2'S\*,6'S\*,8'S\*)-8'-(hydroxymethyl)-1',7'-dioxaspiro[5.5]undecan-2'-yl}-1*H*-1,2,3-triazole-4,5-dicarboxylate (7e)

Method C: The *title compound* 7e (3.50 mg, 69%) was prepared as a pale yellow oil from TBDPS-protected triazole 14e (8.30 mg, 13.7 mmol) and 3HF•NEt<sub>3</sub> (3 x 34 µL) in anhydrous THF (300 µL) using the general procedure (method C) described above. Purification was carried out by flash chromatography using hexane–EtOAc (4:1, 1:1 to 0:1) as eluent followed by PLC using Et<sub>2</sub>O as eluent. HRMS (FAB): found MH<sup>+</sup>, 370.1615, C<sub>16</sub>H<sub>24</sub>N<sub>3</sub>O<sub>7</sub> requires 370.1614.  $\nu_{max}$  (film)/cm<sup>-1</sup>: 3439br (O–H), 2953 (C–H), 1739 (C=O), 1462, 1290, 1258, 1229, 1204 (C–O), 1105 (C–O), 984.  $\delta_{\rm H}$ 

(400 MHz; CDCl<sub>3</sub>): 1.31–1.39 (1 H, m, 9'-H<sub>A</sub>), 1.45–1.55 (2 H, m, 9'-H<sub>B</sub> and 11'-H<sub>A</sub>), 1.55–1.65 (2 H, m, 5'-H<sub>A</sub> and 10'-H<sub>A</sub>), 1.68–1.90 (5 H, m, 4'-H<sub>A</sub>, 5'-H<sub>B</sub>, 10'-H<sub>B</sub>, 11'-H<sub>B</sub> and OH), 2.05–2.19 (2 H, m, 3'-H<sub>A</sub> and 4'-H<sub>B</sub>), 2.28–2.40 (1 H, m, 3'-H<sub>B</sub>), 3.56–3.60 (1 H, m, 8'-*CH*<sub>A</sub>H<sub>B</sub>O), 3.68 (1 H, d,  $J_{AB}$  11.7, 8'-CH<sub>A</sub>H<sub>B</sub>O), 3.76–3.82 (1 H, m, 8'-H), 3.97 (3 H, s, OMe), 4.00 (3 H, s, OMe), 6.15 (1 H, dd,  $J_{2'ax,3'ax}$  11.2 and  $J_{2'ax,3'eq}$  2.7, 2'-H<sub>ax</sub>).  $\delta_{C}$  (100 MHz; CDCl<sub>3</sub>): 17.8 (2 x CH<sub>2</sub>, C-4' and C-10'), 26.0 (CH<sub>2</sub>, C-9'), 30.1 (CH<sub>2</sub>, C-3'), 34.3 (CH<sub>2</sub>, C-5'), 34.6 (CH<sub>2</sub>, C-11'), 52.6 (CH<sub>3</sub>, OMe), 53.6 (CH<sub>3</sub>, OMe), 66.0 (CH<sub>2</sub>, 8'-CH<sub>2</sub>O), 71.0 (CH, C-8'), 82.2 (CH, C-2'), 99.5 (C, C-6'), 131.5 (C, C-5), 138.5 (C, C-4), 159.9 (C, C=O), 160.3 (C, C=O). *m*/*z* (FAB): 370 (MH<sup>+</sup>, 3%), 354 (M – Me, 2), 185 (C<sub>10</sub>H<sub>17</sub>O<sub>3</sub>, 100), 149 (61), 137 (29), 127 (27), 121 (18), 95 (18), 85 (41), 71 (76).

# 1-{(2'S\*,6'S\*,8'S\*)-8'-(Hydroxymethyl)-1',7'-dioxaspiro[5.5]undecan-2'-yl}-1*H*-1,2,3triazole (7f)

Method C: The *title compound* **7f** (3.00 mg, 86%) was prepared as a pale yellow oil from TBDPS-protected triazole **14f** (7.80 mg, 13.8 µmol) and 3HF•NEt<sub>3</sub> (41.0 µL) in anhydrous THF (300 µL) using the general procedure (method C) described above. Purification was carried out by flash chromatography using hexane–EtOAc (4:1, 1:1 to 0:1) as eluent. HRMS (EI): found M<sup>++</sup>, 253.1427, C<sub>12</sub>H<sub>19</sub>N<sub>3</sub>O<sub>3</sub> requires 253.1426.  $v_{max}$  (film)/cm<sup>-1</sup>: 3390 (O–H), 2944 (C–H), 2873, 1456, 1387, 1220, 1201 (C–O), 1066 (C–O), 1047, 979.  $\delta_{\rm H}$  (400 MHz; CDCl<sub>3</sub>): 1.34–1.43 (1 H, m, 9'-H<sub>A</sub>), 1.44–1.64 (4 H, m, 5'-H<sub>A</sub>, 9'-H<sub>B</sub>, 10'-H<sub>A</sub> and 11'-H<sub>A</sub>), 1.72–1.86 (4 H, m, 4'-H<sub>A</sub>, 5'-H<sub>B</sub>, 10'-H<sub>B</sub> and 11'-H<sub>B</sub>), 1.88–2.03 (2 H, m, 3'-H<sub>A</sub> and OH), 2.07–2.21 (2 H, m, 3'-H<sub>B</sub> and 4'-H<sub>B</sub>), 3.58 (1 H, dd,  $J_{\rm AB}$  11.3 and  $J_{8'-CH_2,8'}$  6.2, 8'-*CH*<sub>4</sub>H<sub>B</sub>O), 3.71 (1 H, d,  $J_{\rm AB}$  11.3, 8'-*C*H<sub>A</sub>*H*<sub>B</sub>O), 3.85–3.91 (1 H, m, 8'-H), 6.03 (1 H, dd,  $J_{2'ax,3'ax}$  11.0 and  $J_{2'ax,3'eq}$  2.5, 2'-H<sub>ax</sub>), 7.74 (1 H, d,  $J_{4,5}$  9.7, 4-H), 7.74 (1 H, d,  $J_{5,4}$  9.7, 5-H).  $\delta_{\rm C}$  (100 MHz; CDCl<sub>3</sub>): 17.9 (CH<sub>2</sub>, C-10'), 18.1 (CH<sub>2</sub>, C-4'), 26.0 (CH<sub>2</sub>, C-9'), 30.9 (CH<sub>2</sub>, C-3'), 34.4 (CH<sub>2</sub>, C-5'), 34.6 (CH<sub>2</sub>, C-11'), 66.0 (CH<sub>2</sub>, 8'-CH<sub>2</sub>O), 70.8 (CH, C-8'), 81.1 (CH, C-2'), 99.0 (C, C-6'), 121.5 (CH, C-5), 133.7 (CH, C-4). *m/z* (EI): 253 (M<sup>++</sup>, 9%), 222 (M – CH<sub>2</sub>OH, 7), 185 (C<sub>10</sub>H<sub>17</sub>O<sub>3</sub>, 29), 156 (57), 128 (100), 109 (20), 99 (39), 97 (62), 95 (32), 80 (27), 70 (64), 67 (40), 55 (50), 41 (94).

## Ethyl 1-{(2'*S*\*,6'*S*\*,8'*S*\*)-8'-(hydroxymethyl)-1',7'-dioxaspiro[5.5]undecan-2'-yl}-1*H*-1,2,3-triazole-5-carboxylate (7g)

Method D: The *title compound* **7g** (2.40 mg, 93%) was prepared as a pale yellow oil from TBDPS-protected triazole **14g** (5.00 mg, 7.86  $\mu$ mol), 3HF•NEt<sub>3</sub> (16.0 + 8.00  $\mu$ L) and NEt<sub>3</sub> (20.0 + 10.0  $\mu$ L) in anhydrous THF (700  $\mu$ L) using the general procedure (method D) described above. Purification was carried out by flash chromatography using hexane–EtOAc (4:1, 3:2 to 1:4) as eluent.

HRMS (EI): found  $M^{+\bullet}$ , 325.1636,  $C_{15}H_{23}N_3O_5$  requires 325.1638.  $v_{max}$  (film)/cm<sup>-1</sup>: 3411br (O–H), 2925 (C–H), 2853, 1732 (C=O), 1309, 1258, 1194 (C–O), 1082 (C–O), 984.  $\delta_H$  (300 MHz; CDCl<sub>3</sub>): 1.29–1.36 (1 H, m, 9'-H<sub>A</sub>), 1.40 (3 H, t,  $J_{CH_3,CH_2}$  7.1, OCH<sub>2</sub>*CH*<sub>3</sub>), 1.44–1.70 (4 H, m, 5'-H<sub>A</sub>, 9'-H<sub>B</sub>, 10'-H<sub>A</sub> and 11'-H<sub>A</sub>), 1.71–1.89 (4 H, m, 4'-H<sub>A</sub>, 5'-H<sub>B</sub>, 10'-H<sub>B</sub> and 11'-H<sub>B</sub>), 1.93–2.01 (1 H, m, 3'-H<sub>A</sub>), 2.09–2.24 (2 H, m, 4'-H<sub>B</sub> and OH), 2.53–2.68 (1 H, m, 3'-H<sub>B</sub>), 3.59 (1 H, dd,  $J_{AB}$  11.6 and  $J_{8'-CH_2,8'}$  6.5, 8'-*CH*<sub>4</sub>H<sub>B</sub>O), 3.75 (1 H, dd,  $J_{AB}$  11.6 and  $J_{8'-CH_2,8'}$  3.3, 8'-CH<sub>A</sub>H<sub>B</sub>O), 3.95–4.14 (1 H, m, 8'-H), 4.4 (2 H, q,  $J_{CH_2,CH_3}$  7.1, OCH<sub>2</sub>CH<sub>3</sub>), 6.74 (1 H, dd,  $J_{2'ax,3'ax}$  11.4 and  $J_{2'ax,3'aq}$  2.5, 2'-H<sub>ax</sub>), 8.14 (1 H, s, 4-H).  $\delta_C$  (100 MHz; CDCl<sub>3</sub>): 14.1 (CH<sub>3</sub>, OCH<sub>2</sub>*CH*<sub>3</sub>), 18.2 (CH<sub>2</sub>, C-10'), 18.3 (CH<sub>2</sub>, C-4'), 26.3 (CH<sub>2</sub>, C-9'), 29.6 (CH<sub>2</sub>, C-3'), 34.6 (CH<sub>2</sub>, C-5' or C-11'), 34.6 (CH<sub>2</sub>, C-5' or C-11'), 62.1 (CH<sub>2</sub>, OCH<sub>2</sub>CH<sub>3</sub>), 66.4 (CH<sub>2</sub>, 8'-CH<sub>2</sub>O), 70.8 (CH, C-8'), 79.8 (CH, C-2'), 99.4 (C, C-6'), 127.6 (C, C-5), 137.9 (CH, C-4), 158.6 (C, C=O). *m/z* (EI): 325 (M<sup>+•</sup>, 2%), 252 (M – CO<sub>2</sub>Et, 11), 185 (C<sub>10</sub>H<sub>17</sub>O<sub>3</sub>, 3), 184 (34), 156 (35), 153 (30), 142 (56), 128 (100), 99 (93), 97 (64), 95 (57), 71 (52), 70 (48), 67 (40), 55 (71), 41 (66).

#### Reference

1. W. L. F. Armarego and D. D. Perrin, *Purification of Laboratory Chemicals*, 4th edn., Pergamon, Oxford, UK, 1997.